Company profile
Actavia Life Sciences, Inc.
OTC: RASP · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ 7GM —SS 26
v0.1 · 25/100 weight · pillars only
↑ listing tenure, market scale · ↓ workforce scale, return on assets
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$4.4M
Employees
1
as of 2026-08-27
Market cap
$385.9k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02018
Net income-$4.4M-$4.4M2023
Operating income-$4.2M-$4.2M2023
Total assets$95.7k$95.7k2023
Liabilities$2.1M$2.1M2023
Equity-$2.0M-$2.0M2023
Revenue trend
FY2017 – FY2018 · USD
FY17
FY17
FY17
FY17
FY18
FY17
FY18
FY18
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Actavia Life Sciences, Inc.’s revenue?
Actavia Life Sciences, Inc. booked $0 in FY2018 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Apptly Health Technologies Corp.——Pond Technologies Holdings Inc.21DAlternative Energy Partners, Inc.——Biocure Technology Inc.——Marijuana Inc.——Bakhu Holdings, Corp.——Neighbors
New York →Key facts
CEOKeeren Shah
SectorHealthcare
IndustryBiotechnology
HeadquartersNew York City, NY
ExchangeOTC: RASP
Employees1
IPO date2015-02-24
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.